2025 was a standout year for AbbVie. Despite the global pharmaceutical market facing patent cliffs and intensified competition, the company achieved strong growth through a diversified product portfolio and disciplined operational strategy. Full-year net revenue reached $61.16 billion, with fourth-quarter revenue of $16.62 billion, up 10.0% year-over-year. AbbVie Chairman and CEO Robert A. Michael commented: “2025 marks another exceptional year for AbbVie. In the second full year since Humira lost exclusivity in the U.S., we achieved record net sales, highlighting the strength of our diversified growth platform.” This article provides a comprehensive analysis of AbbVie’s 2025 performance, covering financial results, product performance, regional markets, cost efficiency, and future outlook.
AbbVie delivered solid financial performance in 2025, driven by volume growth in core products and disciplined cost management. Global net revenue in Q4 reached $16.62 billion, up 10.0% on a reported basis (or 9.5% operationally) from $15.10 billion in Q4 2024. Full-year net revenue totaled $61.16 billion, an 8.6% increase on a reported basis. Growth was fueled by strong contributions from the immunology and neuroscience portfolios, particularly Skyrizi and Rinvoq.
On the profitability front, Q4 GAAP operating margin was 27.3%, while adjusted operating margin improved to 38.3%, reflecting enhanced operational efficiency. GAAP EPS for the quarter was $1.02, with adjusted EPS of $2.71; full-year GAAP EPS was $2.36, and adjusted EPS reached $10.00. The improvement in non-GAAP metrics was largely due to amortization adjustments and the exclusion of one-time items, such as reduced acquisition-related expenses.
Cash flow remained strong, supporting both R&D investment and shareholder returns. By segment, Q4 immunology revenue was $8.63 billion, up 18.3%, becoming the primary growth driver. Neuroscience revenue reached $2.96 billion, up 17.9%. Oncology revenue faced pressure, declining 1.5% to $1.66 billion, while aesthetics revenue remained largely flat at $1.29 billion. AbbVie’s diversified portfolio effectively offset the decline in Humira revenue, which fell 25.9% in Q4 to $1.25 billion.
AbbVie’s diversified product strategy showed strong results in 2025, with key products contributing across multiple therapeutic areas.
Immunology was the core growth driver. Skyrizi delivered $5.01 billion in Q4 revenue, up 32.5%, benefiting from expanded psoriasis and arthritis indications. Rinvoq generated $2.37 billion, up 29.5%, as penetration in atopic dermatitis and rheumatoid arthritis continued to grow. Despite biosimilar competition, Humira remained a significant cash generator. Immunology products accounted for over 35% of full-year revenue, highlighting their strategic importance.
Neuroscience also grew steadily. Q4 Vraylar revenue reached $1.02 billion (+10.5%), Botox Therapeutic reached $990 million (+13.4%), and migraine treatments Ubrelvy and Qulipta grew 12.0% and 42.6%, respectively. Full-year neuroscience revenue totaled $10.77 billion, the second-largest segment.
Oncology faced challenges. Q4 revenue totaled $1.66 billion, down 1.5%. Imbruvica revenue fell 20.8% to $671 million, while Venclexta grew 8.6% to $710 million, partially offsetting the decline. New product Elahere generated $182 million (+22.6%), demonstrating pipeline potential.
Aesthetics saw mixed results. Botox Cosmetic grew 4.2% to $717 million, while Juvederm declined 10.7% to $249 million due to competitive pressures. AbbVie continued product innovation, including approval of Epkinly combination therapy for lymphoma and a new Rinvoq submission for vitiligo, laying a foundation for future growth.
The U.S. remained AbbVie’s primary revenue source, but international markets posted strong growth. Q4 U.S. revenue reached $12.79 billion (+9.0%), while international revenue rose 13.5% to $3.82 billion. On an operational basis (excluding currency effects), U.S. growth was 8.3%, and international growth was 11.0%, reflecting successful global expansion strategies.
Star products Skyrizi and Rinvoq grew faster internationally than in the U.S. Q4 international revenue for Skyrizi was $651 million (+39.8%), and Rinvoq was $665 million (+36.4%), driven by channel expansion in Europe and the Asia-Pacific region. AbbVie recently submitted Rinvoq for vitiligo treatment to EU regulators, potentially further opening international markets.
In the U.S., Humira revenue declines were offset by new products, and AbbVie stabilized its base through healthcare partnerships. In 2025, the company reached a voluntary agreement with the U.S. government to offer low-cost drugs under Medicaid and pledged $100 billion in R&D and capital investment in the U.S. over the next decade in exchange for tariff exemptions and pricing protections, mitigating policy risks.
AbbVie’s margin gains in 2025 were supported by disciplined cost management. Q4 GAAP gross margin was 72.6%, with adjusted gross margin of 83.6%, driven by production efficiency and portfolio optimization.
Operating expenses were well-controlled: SG&A was 23.4% of revenue, and R&D 15.5%, both lower than 2024. Adjusted SG&A and R&D ratios were 22.3% and 15.4%, reflecting operational leverage. Non-GAAP adjustments excluded one-time items such as intangible asset amortization and acquisition-related costs.
Q4 acquisition-related IPR&D and milestone expenses totaled $1.27 billion, negatively impacting EPS by $0.71. Excluding these, adjusted operating margin reached 38.3%, highlighting the profitability of core operations. Strong operational cash flow supported dividend increases (6% growth in 2025) and stock buybacks. Strategic acquisitions, including licensing RC148 (PD-1/VEGF bispecific antibody) from RemeGen and acquiring West company’s equipment plant, expanded the pipeline and production capacity, with long-term cost benefits.
Based on 2025 results, AbbVie provided optimistic guidance for 2026. The company expects adjusted diluted EPS of $14.37–$14.57, up ~44%, reflecting confidence in growth. This assumes single-digit revenue growth and continued margin improvement.
Key R&D initiatives include:
Rinvoq for vitiligo: Phase III Viti-UP trial met primary endpoints, with expected approval in 2026 as a potential first-in-class therapy.
Epkinly combination therapy: Ongoing Phase III lymphoma study, exploring small-cell lung cancer indications.
Neuroscience: Qulipta and Ubrelvy international expansion supports segment growth.
Next-generation technology: Collaborations with Genmab on bispecific antibodies and AI-driven clinical trial optimization.
CEO Robert Michael stated: “With strong fundamentals, we expect 2026 to be another year of solid growth. This momentum, combined with innovation investments, lays the foundation for AbbVie’s long-term success.”
Challenges remain, including intensified oncology competition and potential Imbruvica revenue decline. Global pricing pressures and currency fluctuations are additional risks. AbbVie plans to address these through cost savings and differentiated products, such as expanding convenient subcutaneous therapies.
